A Randomized Double-blind Placebo controlled Multi-center 2-part Phase 2 Study to Evaluate Efficacy Safety and Tolerability of RGH-706 in Prader-Willi Syndrome

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prader-willi Syndrome
  • Age: Between 17 Year(s) - 65 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Genetically confirmed diagnosis of PWS
    2. Body weight =40 kg/88 lbs and ≤200 kg/450 lbs
    3. Stable body weight, self or caregiver-reported weight change ≤5% in the previous 3 months.
    4. If a patient has a cu

You may not be eligible for this study if the following are true:

    1. Hypersensitivity to RGH-706 or any of the excipients (gelatin, starch, or magnesium stearate)
    2. Severe psychiatric disorders (eg, schizophrenia, bipolar disorder, or major depressive disorder), recent (within 6 months) psychotic or


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.